I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: October 23, 2002

Docket No.: 28110/36858A

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ford et al.

Application No.: 10/003,671

Group Art Unit: 1614

Filed: November 2, 2001 Projected Examiner: To be

determined

For: **NOVEL INTERLEUKIN-1 HY2 MATERIALS AND METHODS**

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents Washington, DC 20231

Dear Sir:

Submitted herewith is a Form PTO-1449 listing several documents. Copies of documents B1-B2 and C1-C3 have been submitted in the parent application no. 09/316,081, filed May 20, 1999 and pursuant to 37 CFR §1.98(d), copies are not submitted herewith. Copies of documents C4-C6 are submitted herewith.

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein constitutes prior art under 35 USC §102 or §103.

Application No.: 10/003,671 Docket No.: 28110/36858A

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed to be due under 37 CFR §1.97 (b) because this statement and Form PTO-1449 are being submitted before receipt of a first office action on the merits in the above-identified patent application. However, the Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: October 23, 2002

Respectfully submitted,

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agents for Applicant

		SHEET TOLL	
Form PTO-1449 (Modified)	Atty. Docket No. 28110/36858A	Serial No. 10/003,671	
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Mize et al.		
DIPE	Filing Date November 2, 2001	Art Unit 1614	

DIPE				Filing Date Novembe	er 2, 2001	Art Unit 1614
OCT 2 8 2002	1 1 1 1 1 1 1 1 1 1					
& TRADEMARIA	/	U.S. PA	TENT DOCUN	1ENTS		
Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate
	RECEI	VED				
	OCT 2'9	2002				
TE(H CENTER 16	300/2000				
	111	YU12900				

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Document Number	Publication Date	Country	Transl	ation
				Yes	No
B1	WO 98/347921	10/29/1998	WO		
B2	WO 99/51744	10/14/1999	WO		

OTHER DOCUMENTS				
C1		Carter et al., Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein, Nature 344: 633-638 (April 12, 1990).		
C2		Genebank Accession No.: AC016724, <i>Homo sapiens</i> chromosome 2 clone RP11-339F22, Working Draft Sequence, 12 unordered pieces, deposited by Waterston, R.H., dated 07 July 2000.		
C3		Genebank Accession No.: AQ766579, Human Genomic Sperm Library: deposited by Mahairas G.G. et al., dated 30 July 1999.		
C4	4	Boraschi et al., Structure-Function Relationship in the IL-1 Family, Frontiers in Bioscience 1, d270-308, (October 1, 1995).		
C5	4	Jensen et al., IL-1 Signaling Cascade in Liver Cells and the Involvement of a Soluble Form of the IL-1 Receptor Accessory Protein ^{1,2} , J. Immunol., 5277-5286 (2000).		
C6	Ý	Vigers et al., Crystal Structure of the Type-I Interleukin-1 Receptor Complexed With Interleukin-1β, Nature 386: 190-194 (March 13, 1997).		

EXAMINER:	DATE CONSIDERED: